Vintafolide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Vintafolide API 742092-03-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Vintafolide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Vintafolide
- Synonyms:
- Cas Number:
- 742092-03-1
- DrugBank number:
- DB05168
- Unique Ingredient Identifier:
- 36O410ZD4I
General Description:
Vintafolide, identified by CAS number 742092-03-1, is a notable compound with significant therapeutic applications. Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in solid tumors. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Vintafolide functions by: Vintafolide minimizes the off-target toxicity by delivering the vinca molecule directly and specifically to cancer cells that over-express the folate-receptor. Once delivered to the cancer cell surface, Vintafolide is internalized into the cancer cell via endocytosis, a natural cellular process. Once inside the cell, Endocyte’s proprietary linker technology releases the chemotherapy to eliminate the cancer cell. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Vintafolide belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together, classified under the direct parent group Vinca alkaloids. This compound is a part of the Organic compounds, falling under the Alkaloids and derivatives superclass, and categorized within the Vinca alkaloids class, specifically within the None subclass.
Categories:
Vintafolide is categorized under the following therapeutic classes: Alkaloids, Antineoplastic Agents, Antineoplastic and Immunomodulating Agents, Heterocyclic Compounds, Fused-Ring, Indole Alkaloids, Indoles, Indolizidines, Indolizines, Pteridines, Pterins, Secologanin Tryptamine Alkaloids, Vinca Alkaloids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Vintafolide is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
